Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data Base

Gaurav Goyal, Peter T. Silberstein, James O. Armitage

Research output: Contribution to journalArticle

5 Scopus citations


Background Hodgkin lymphoma (HL) has come a long way from being a disease with high mortality to being highly curable, which thereby exposes survivors to the potential for long-term toxicities. Our aim was to analyze the National Cancer Data Base for trends in radiation therapy use among all stages of HL from 2000 to 2012 and to see if increased recognition of these risks has decreased the use of radiation therapy. Patients and Methods This was a retrospective study of patients diagnosed with HL (stage I-IV) between the years 2000 and 2012 using the National Cancer Data Base (n = 24,118). The National Cancer Data Base is a nationwide oncology outcomes database for more than 1500 American College of Surgeons Commission on Cancer accredited cancer programs. The study focused on the proportion of patients who received radiation therapy. Results Between the years 2000 and 2012, use of radiation therapy declined among all stages of HL (stage I: 53% to 40%, P =.0002; stage II: 52% to 36%, P <.0001; stage III: 21% to 10%, P <.0001; stage IV: 17% to 9%; P =.0002). Conclusion There has been a significant decline in the use of radiation therapy from 2000 to 2012 among all stages of HL, perhaps because of the studies that showed an increase in late complications with use of radiation therapy.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number1
StatePublished - Jan 1 2016



  • Adult
  • Cardiotoxicity
  • Complications
  • Radiotherapy
  • Survivors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this